Fetal hemoglobin inducing factors;Agentes indutores da síntese de hemoglobina fetal

Revista Brasileira de Hematologia e Hemoterapia

Volumn 29, Issue 3, 2007, Pages 313-315

  Figueiredo, Maria Stella ^a,b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

HbF synthesis; Hydroxyurea; Sickle cell anemia; Treatment

Indexed keywords

EID: 38049129796     PISSN: 15168484     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Perrine RP, Pembrey ME, John P, Perrine S, Shoup F. Natural history of sickle cell anemia in Saudi Arabs. A study of 270 subjects. Ann Intern Med. 1978; 88:1-6.
2. Wood WG, Pembrey ME, Serjeant GR, Perrine RP, Weatherall DJ. HbF synthesis in sickle cell anaemia: a comparison of Saudi Arab cases with those of African origin. Br J Haematol. 1980;45:431-45.
3. Powars DR, Chan L, Schroeder WA. The influence of fetal hemoglobin on the clinical expression of sickle cell anemia. Ann N Y Acad Sci. 1989;565:262-78.
4. Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994;330:1639-44.
5. Adekile AD, Huisman THJ. Hb F in sickle cell anemia. Experientia. 1993;49:16-27.
6. Bunn HF, Forget BG. Hemoglobin: molecular, genetic and clinical aspects. W.B. Saunders Company, Primeira edição, 1986, 690 p.
7. Stamatoyannopoulos G, Nienhuis AW, Majerus PW, Varnus H. The molecular basis of blood disease. WB Saunders Company. Segunda edição, 1994, 982 p.
8. DeSimone J, Heller P, Hall L, Zwiers D. 5-Azacytidine stimulates fetal hemoglobin synthesis in anemic baboons. Proc Natl Acad Sci USA. 1982;79:4428-31.
9. Schechter AN, Rodgers GP. Sickle cell anemias - basic research reaches the clinic. N Engl J Med. 1995;332:1372-4.
10. Charache S, Dover GJ, Moore RD, Eckert S, Ballas SK, Koshy M, et al. Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. Blood. 1992;79:2555-65.
11. Stamatoyannopoulos G, Nienhuis AW. Therapeutic approaches to hemoglobin switching in treatment of hemoglobinopathies. Ann Rev Med 1992;43:497-521.
12. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, et al. The Investigators of The Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med. 1995; 332: 1313-22.
13. Charache S, Barton FB, Moore RD, Terrin ML, Steinberg MH, Dover GJ, et al. The Investigators of The Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. Medicine. 1995;75:300-26.
14. Davies SC, Gilmore A. The role of hydroxyurea in the managemenet of sickle cell disease. Blood Rev. 2003;17:99-109.
15. Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia. Risk and benefits up to 9 years of treatment. JAMA 2003;289:1645-51.
16. Aliyu ZY, Tumblin AR, Kato GJ. Current therapy of sickle cell disease. Haematologica. 2005;90:7-12.
17. Stuart MJ, Nagel R. Sickle-cell disease. Lancet. 2004;364:1343-60.
18. Halsey C, Roberts IAG. The role of hydroxyurea in sickle cell disease. Br J Haematol. 2003;120:177-86.
19. Weinberg RS, Ji X, Sutton M, Perrine S, Galperin Y, Li Q, et al. Butyrate increases the efficiency of translation of gamma-globin mRNA. Blood 2005;105:1807-9.
20. Steinberg MH. Pathophysiologically based drug tratment of sickle cell disease. TRENDS Pharmacol Sci. 2006;27:204-10.
21. Atweh GF, Sutton M, Nassif I, Boosalis V, Dover GJ, Wallenstein S, et al. Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease. Blood 1999;93:1790-7.
22. Saunthararajah Y, DeSimone J. Clinical studies with fetal hemoglobin-enhancing agents in sickle cell disease. Semin Hematol 2004;41(4 suppl 6):11-6.